Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2008 1
2009 2
2010 2
2011 4
2012 14
2013 36
2014 62
2015 75
2016 82
2017 58
2018 78
2019 106
2020 136
2021 127
2022 112
2023 112
2024 21

Text availability

Article attribute

Article type

Publication date

Search Results

885 results

Results by year

Filters applied: . Clear all
Page 1
Once-weekly tirzepatide versus once-daily insulin degludec as add-on to metformin with or without SGLT2 inhibitors in patients with type 2 diabetes (SURPASS-3): a randomised, open-label, parallel-group, phase 3 trial.
Ludvik B, Giorgino F, Jódar E, Frias JP, Fernández Landó L, Brown K, Bray R, Rodríguez Á. Ludvik B, et al. Lancet. 2021 Aug 14;398(10300):583-598. doi: 10.1016/S0140-6736(21)01443-4. Epub 2021 Aug 6. Lancet. 2021. PMID: 34370970 Clinical Trial.
BACKGROUND: Tirzepatide is a novel dual glucose-dependent insulinotropic polypeptide and GLP-1 receptor agonist under development for the treatment of type 2 diabetes. We aimed to assess the efficacy and safety of tirzepatide versus titrated insulin degludec …
BACKGROUND: Tirzepatide is a novel dual glucose-dependent insulinotropic polypeptide and GLP-1 receptor agonist under development for …
Diabetic vascular diseases: molecular mechanisms and therapeutic strategies.
Li Y, Liu Y, Liu S, Gao M, Wang W, Chen K, Huang L, Liu Y. Li Y, et al. Signal Transduct Target Ther. 2023 Apr 10;8(1):152. doi: 10.1038/s41392-023-01400-z. Signal Transduct Target Ther. 2023. PMID: 37037849 Free PMC article. Review.
Vascular complications of diabetes pose a severe threat to human health. Prevention and treatment protocols based on a single vascular complication are no longer suitable for the long-term management of patients with diabetes. ...DPDs are proposed for patients to ob …
Vascular complications of diabetes pose a severe threat to human health. Prevention and treatment protocols based on a single vascula …
Type 2 diabetes mellitus and cognitive function: understanding the connections.
Dao L, Choi S, Freeby M. Dao L, et al. Curr Opin Endocrinol Diabetes Obes. 2023 Feb 1;30(1):7-13. doi: 10.1097/MED.0000000000000783. Epub 2022 Nov 17. Curr Opin Endocrinol Diabetes Obes. 2023. PMID: 36385094 Review.
Unfortunately, there is a lack of evidence-based guidance on the prevention of cognitive dysfunction in the diabetes population. Studies of diabetes medications, including metformin, glucagon-like peptide-1 (GLP-1) receptor agonists, and sodium-glucose cotran …
Unfortunately, there is a lack of evidence-based guidance on the prevention of cognitive dysfunction in the diabetes population. Stud …
Effects of Antidiabetic Drugs on Muscle Mass in Type 2 Diabetes Mellitus.
Ida S, Kaneko R, Imataka K, Okubo K, Shirakura Y, Azuma K, Fujiwara R, Murata K. Ida S, et al. Curr Diabetes Rev. 2021;17(3):293-303. doi: 10.2174/1573399816666200705210006. Curr Diabetes Rev. 2021. PMID: 32628589
OBJECTIVE: To comparatively examine the effects of GLP-1RAs and oral antidiabetic drugs, including SGLT2 inhibitors and metformin, on muscle mass and body weight in patients with type 2 diabetes via a network meta-analysis of randomized controlled trials. ...Semaglu …
OBJECTIVE: To comparatively examine the effects of GLP-1RAs and oral antidiabetic drugs, including SGLT2 inhibitors and metformin, on …
Cardiorenal diseases in type 2 diabetes mellitus: clinical trials and real-world practice.
Lim LL, Chow E, Chan JCN. Lim LL, et al. Nat Rev Endocrinol. 2023 Mar;19(3):151-163. doi: 10.1038/s41574-022-00776-2. Epub 2022 Nov 29. Nat Rev Endocrinol. 2023. PMID: 36446898 Review.
Patients with type 2 diabetes mellitus (T2DM) can have multiple comorbidities and premature mortality due to atherosclerotic cardiovascular disease, hospitalization with heart failure and/or chronic kidney disease. Traditional drugs that lower glucose, …
Patients with type 2 diabetes mellitus (T2DM) can have multiple comorbidities and premature mortality due to ath …
First-Line Therapy for Type 2 Diabetes With Sodium-Glucose Cotransporter-2 Inhibitors and Glucagon-Like Peptide-1 Receptor Agonists : A Cost-Effectiveness Study.
Choi JG, Winn AN, Skandari MR, Franco MI, Staab EM, Alexander J, Wan W, Zhu M, Huang ES, Philipson L, Laiteerapong N. Choi JG, et al. Ann Intern Med. 2022 Oct;175(10):1392-1400. doi: 10.7326/M21-2941. Epub 2022 Oct 4. Ann Intern Med. 2022. PMID: 36191315 Free PMC article.
RESULTS OF BASE-CASE ANALYSIS: First-line SGLT2 inhibitors and GLP1 receptor agonists had lower lifetime rates of congestive heart failure, ischemic heart disease, myocardial infarction, and stroke compared with metformin. First-line SGLT2 inhibitors cost $43 000 more and …
RESULTS OF BASE-CASE ANALYSIS: First-line SGLT2 inhibitors and GLP1 receptor agonists had lower lifetime rates of congestive heart failure, …
Cardiovascular Outcomes in Patients Initiating First-Line Treatment of Type 2 Diabetes With Sodium-Glucose Cotransporter-2 Inhibitors Versus Metformin : A Cohort Study.
Shin H, Schneeweiss S, Glynn RJ, Patorno E. Shin H, et al. Ann Intern Med. 2022 Jul;175(7):927-937. doi: 10.7326/M21-4012. Epub 2022 May 24. Ann Intern Med. 2022. PMID: 35605236
BACKGROUND: Evidence on the risk for cardiovascular events associated with use of first-line sodium-glucose cotransporter-2 inhibitors (SGLT-2i) compared with metformin is limited. OBJECTIVE: To assess cardiovascular outcomes among adults with type 2 diabetes (T2D) …
BACKGROUND: Evidence on the risk for cardiovascular events associated with use of first-line sodium-glucose cotransporter-2 inhibitors (SGLT …
Diabetes management in chronic kidney disease: a consensus report by the American Diabetes Association (ADA) and Kidney Disease: Improving Global Outcomes (KDIGO).
de Boer IH, Khunti K, Sadusky T, Tuttle KR, Neumiller JJ, Rhee CM, Rosas SE, Rossing P, Bakris G. de Boer IH, et al. Kidney Int. 2022 Nov;102(5):974-989. doi: 10.1016/j.kint.2022.08.012. Epub 2022 Oct 3. Kidney Int. 2022. PMID: 36202661
Recent clinical trials support new approaches to treat diabetes and CKD. The 2022 American Diabetes Association (ADA) Standards of Medical Care in Diabetes and the Kidney Disease: Improving Global Outcomes (KDIGO) 2022 Clinical Practice Guideline for Diabe
Recent clinical trials support new approaches to treat diabetes and CKD. The 2022 American Diabetes Association (ADA) Standard …
Sweet and simple as syrup: A review and guidance for use of novel antihyperglycemic agents for post-transplant diabetes mellitus and type 2 diabetes mellitus after kidney transplantation.
Lawrence SE, Chandran MM, Park JM, Sweiss H, Jensen T, Choksi P, Crowther B. Lawrence SE, et al. Clin Transplant. 2023 Mar;37(3):e14922. doi: 10.1111/ctr.14922. Epub 2023 Feb 13. Clin Transplant. 2023. PMID: 36708369 Review.
Uncontrolled type 2 diabetes mellitus (T2DM) and post-transplant diabetes mellitus (PTDM) increase morbidity and mortality after kidney transplantation. Conventional strategies for diabetes management in this population include …
Uncontrolled type 2 diabetes mellitus (T2DM) and post-transplant diabetes mellitus (PTDM) increase …
Cardiovascular outcomes associated with SGLT-2 inhibitors versus other glucose-lowering drugs in patients with type 2 diabetes: A real-world systematic review and meta-analysis.
Li CX, Liang S, Gao L, Liu H. Li CX, et al. PLoS One. 2021 Feb 19;16(2):e0244689. doi: 10.1371/journal.pone.0244689. eCollection 2021. PLoS One. 2021. PMID: 33606705 Free PMC article.
Therefore, in this meta-analysis, we analyzed the real-world effect of SGLT-2i on cardiovascular outcome in patients with type 2 diabetes mellitus (T2DM). METHODS: We did a real-world systematic review and meta-analysis of cardiovascular outcome of SGL …
Therefore, in this meta-analysis, we analyzed the real-world effect of SGLT-2i on cardiovascular outcome in patients with type 2
885 results